199 related articles for article (PubMed ID: 29317666)
1. Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing.
Schoergenhofer C; Schwameis M; Firbas C; Bartko J; Derhaschnig U; Mader RM; Plaßmann RS; Jilma-Stohlawetz P; Desai K; Misra P; Jäger U; Jilma B
Sci Rep; 2018 Jan; 8(1):124. PubMed ID: 29317666
[TBL] [Abstract][Full Text] [Related]
2. GP2013: A Rituximab Biosimilar.
Blair HA
BioDrugs; 2017 Oct; 31(5):465-468. PubMed ID: 28921160
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.
Burmester G; Chien D; Chow V; Gessner M; Pan J; Cohen S
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1003-1014. PubMed ID: 32627420
[TBL] [Abstract][Full Text] [Related]
4. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
Candelaria M; Gonzalez D; Fernández Gómez FJ; Paravisini A; Del Campo García A; Pérez L; Miguel-Lillo B; Millán S
Cancer Chemother Pharmacol; 2018 Mar; 81(3):515-527. PubMed ID: 29362903
[TBL] [Abstract][Full Text] [Related]
5. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
[TBL] [Abstract][Full Text] [Related]
6. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X
Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20
Jiang B; Ke X; Zhang Q; Xu W; Su H; Huang J; Zhang M; Wang H; Jin C; Zhu J; Liu L; Cai Z; Zhao X; Zhou J; Zhang X; Liu J; Zhou H; Yu J; Sun X; Qi J; Qiu L
Sci Rep; 2020 Jul; 10(1):11676. PubMed ID: 32669656
[TBL] [Abstract][Full Text] [Related]
9. Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India.
Nair R; Radhakrishnan VS; Mallath MK
Lancet Haematol; 2021 Aug; 8(8):e548-e549. PubMed ID: 34329574
[No Abstract] [Full Text] [Related]
10. A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers.
Zhou H; Cao S; Zhu X; Xie J; Fan L; Ge Q; Wang Y; Zhu J; Liu Y; Shao Z; Shan R; Liu B; Wang H; Ding L
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):997-1003. PubMed ID: 32847423
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.
Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X
Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067
[TBL] [Abstract][Full Text] [Related]
12. Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany.
Otremba B; Borchardt J; Kuske A; Hollnagel-Schmitz M; Losch FO
Future Oncol; 2020 May; 16(15):1001-1012. PubMed ID: 32286864
[No Abstract] [Full Text] [Related]
13. Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects.
Zhang H; Li Q; Zhu X; Li C; Li X; Liu C; Hu Y; Chen G; Wei H; Wang J; Shen Z; Ding Y
Cancer Chemother Pharmacol; 2018 Oct; 82(4):615-623. PubMed ID: 30043208
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma.
Gota V; Karanam A; Rath S; Yadav A; Tembhare P; Subramanian P; Sengar M; Nair R; Menon H
Cancer Chemother Pharmacol; 2016 Aug; 78(2):353-9. PubMed ID: 27329361
[TBL] [Abstract][Full Text] [Related]
15. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
[TBL] [Abstract][Full Text] [Related]
16. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
[TBL] [Abstract][Full Text] [Related]
17. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab.
Esteva FJ; Stebbing J; Wood-Horrall RN; Winkle PJ; Lee SY; Lee SJ
Cancer Chemother Pharmacol; 2018 Mar; 81(3):505-514. PubMed ID: 29330636
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults.
Wang J; Niu S; Dong W; Wei L; Ou L; Zhang T; Zhang L; Nie X; Wang Q; Shen T; Wang Q; Xia L; Liu G; Jin J; Zheng Q; Song H; Fang Y
Expert Opin Investig Drugs; 2020 Jul; 29(7):755-762. PubMed ID: 32594779
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
20. PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen
Yao HM; Ottery FD; Borema T; Harris S; Levy J; May TB; Moosavi S; Zhang J; Summers M
BioDrugs; 2019 Apr; 33(2):207-220. PubMed ID: 30900158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
